» Articles » PMID: 12857559

Spleen Enlargement Following Recombinant Human Granulocyte Colony-stimulating Factor Administration for Peripheral Blood Stem Cell Mobilization

Overview
Journal Haematologica
Specialty Hematology
Date 2003 Jul 15
PMID 12857559
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used to mobilize peripheral blood stem cells (PBSC) for autologous or allogeneic transplants. Such treatment may cause spleen enlargement; exceptionally, spontaneous spleen rupture has been reported. We investigated changes in spleen size during stem cell mobilization.

Design And Methods: We evaluated spleen size, comparing palpation with ultrasound (US)-evaluated longitudinal diameter and volume, in 13 healthy donors and 22 patients with a hematological malignancy who were undergoing PBSC mobilization with rhG-CSF-including regimens.

Results: Intraobserver and interobserver variability of US-calculated spleen volume was very low; the correlation between the volume calculated by US and that measured by 3-dimensional computed tomography was excellent. During mobilization, spleen enlargement was detected by palpation in 17% of subjects, by US-measured longitudinal diameter in 60%, and by US-calculated volume in 91%. The median increase in spleen volume was 300 mL (range, 54-820; p<0.001) in healthy donors and 135 mL (range, 0-413; p=0.004) in the group of patients; the enlargement correlated with white blood cell count elevation (p=0.016) but not with circulating CD34+ cells. One month after the last administration of rhG-CSF, the median decrease was 160 mL (range, 35-800) in healthy donors and 58 mL (range, 0-310) in patients.

Interpretation And Conclusions: When evaluated by sensitive methods, rhG-CSF caused spleen enlargement in almost all individuals treated. US-calculated volume proved to be an excellent method, much better than longitudinal diameter, for detecting non-palpable splenomegaly induced by rhG-CSF.

Citing Articles

Spleen volume assessment in Ph-negative chronic myeloproliferative neoplasms: a real-life study comparing ultrasonography vs. magnetic resonance imaging scans.

Pugliese N, Cavaliere C, Basso L, Fazio L, Malafronte R, Giordano C Ann Hematol. 2025; 104(1):383-388.

PMID: 39836191 PMC: 11868251. DOI: 10.1007/s00277-024-06177-x.


Elevated granulocyte-colony stimulating factor and hematopoietic stem cell mobilization in Niemann-Pick type C1 disease.

Groenen A, La Rose A, Li M, Bazioti V, Svendsen A, Kloosterhuis N J Lipid Res. 2022; 63(2):100167.

PMID: 35007562 PMC: 8953690. DOI: 10.1016/j.jlr.2021.100167.


Vertebral fracture and splenomegaly in a head and neck cancer producing granulocyte colony-stimulating factor: A case report of systemic complications associated with a cytokine-producing solid tumor.

Kitamura N, Sento S, Sasabe E, Kiyasu K, Nakaji K, Daibata M Mol Clin Oncol. 2021; 15(4):202.

PMID: 34462658 PMC: 8375029. DOI: 10.3892/mco.2021.2364.


Variceal Bleed and Portal Hypertensive Gastropathy in a Noncirrhotic Patient with Isolated Splenomegaly.

Hasan S, Dmitriew M, Leonard J Case Reports Hepatol. 2020; 2020:8893713.

PMID: 33381333 PMC: 7762672. DOI: 10.1155/2020/8893713.


Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment.

Pilatova K, Bencsikova B, Demlova R, Valik D, Zdrazilova-Dubska L Cancer Immunol Immunother. 2018; 67(12):1919-1929.

PMID: 29748897 PMC: 11028306. DOI: 10.1007/s00262-018-2166-4.